Initiator Pharma Past Earnings Performance
Past criteria checks 0/6
Initiator Pharma's earnings have been declining at an average annual rate of -23.9%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-23.9%
Earnings growth rate
-9.5%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | n/a |
| Return on equity | -63.9% |
| Net Margin | n/a |
| Next Earnings Update | 29 Nov 2024 |
Recent past performance updates
Recent updates
We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn
May 31
Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?
Feb 27Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?
May 20Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?
Jan 06We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn
Oct 26We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate
Jun 12Revenue & Expenses Breakdown
How Initiator Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -12 | 4 | 0 |
| 31 Mar 24 | 0 | -18 | 4 | 0 |
| 31 Dec 23 | 0 | -23 | 4 | 0 |
| 30 Sep 23 | 0 | -27 | 3 | 0 |
| 30 Jun 23 | 0 | -29 | 3 | 0 |
| 31 Mar 23 | 0 | -33 | 3 | 0 |
| 31 Dec 22 | 0 | -38 | 3 | 0 |
| 30 Sep 22 | 0 | -40 | 3 | 0 |
| 30 Jun 22 | 0 | -43 | 2 | 0 |
| 31 Mar 22 | 0 | -34 | 2 | 0 |
| 31 Dec 21 | 0 | -21 | 1 | 0 |
| 30 Sep 21 | 0 | -16 | 1 | 0 |
| 30 Jun 21 | 0 | -10 | 1 | 0 |
| 31 Mar 21 | 0 | -8 | 1 | 0 |
| 31 Dec 20 | 0 | -9 | 1 | 0 |
| 30 Sep 20 | 0 | -10 | 1 | 0 |
| 30 Jun 20 | 0 | -9 | 1 | 0 |
| 31 Mar 20 | 0 | -9 | 1 | 0 |
| 31 Dec 19 | 0 | -8 | 1 | 0 |
| 30 Sep 19 | 0 | -7 | 1 | 0 |
| 30 Jun 19 | 0 | -9 | 1 | 0 |
| 31 Mar 19 | 0 | -8 | 1 | 0 |
| 31 Dec 18 | 0 | -10 | 1 | 0 |
| 30 Sep 18 | 0 | -13 | 1 | 0 |
| 30 Jun 18 | 0 | -11 | 1 | 0 |
| 31 Mar 18 | 0 | -10 | 1 | 0 |
| 31 Dec 17 | 0 | -9 | 1 | 0 |
| 30 Sep 17 | 0 | -7 | 1 | 0 |
Quality Earnings: INIT is currently unprofitable.
Growing Profit Margin: INIT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INIT is unprofitable, and losses have increased over the past 5 years at a rate of 23.9% per year.
Accelerating Growth: Unable to compare INIT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INIT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: INIT has a negative Return on Equity (-63.93%), as it is currently unprofitable.